These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy of vaccination against hepatitis A in HIV infected adults from Lodz region--preliminary report].
    Author: Jabłonowska E, Kuydowicz J, Małolepsza E.
    Journal: Przegl Epidemiol; 2008; 62(3):605-12. PubMed ID: 19108525.
    Abstract:
    OBJECTIVE: To estimate the prevalence of anti-HAV-T in the group of HIV-positive adults and to assess the efficacy of vaccination against viral hepatitis A. MATERIAL AND METHODS: In HIV-infected outpatients anti-HAV-T was determined (electrochemiluminescence method). Patients susceptible to HAV infection were qualified for vaccination. RESULTS: In the group of 175 HIV-infected patients, 70 persons (40%) were anti-HAV-T positive. Prevalence of anti-HAV-T was significantly higher in patients over 35 years of age. Anti-HAV-T were present in all individuals older than 50 years. So far 47 patients have completed vaccination. Good response (detectable anti-HAV-T 1 month after booster dose) was obtained in 73,0% patients. Individuals with actual CD4 count above 200 cells/ul responded better (81,2%) than persons with CD4 count 200 cells/ul or lower (20%). Nadir CD4 count above 50 cells/ul predicted better response than 50 cells/ul or below (78,8% and 25% respectively). One year after vaccination anti-HAV-T were still detectable in 21 patients (56,8%). CONCLUSIONS: 1. Most of studied HIV-positive patients (60%) were susceptible to HAV infection and should be vaccinated. 2. Good response to vaccination was obtained in 73% of patients and it was higher in persons with actual CD4 count above 200 cells/ul and nadir CD4 count above 50 cells/ul.
    [Abstract] [Full Text] [Related] [New Search]